2020
DOI: 10.3855/jidc.12425
|View full text |Cite
|
Sign up to set email alerts
|

2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness

Abstract: On 31 December 2019 the Wuhan Health Commission reported a cluster of atypical pneumonia cases that was linked to a wet market in the city of Wuhan, China. The first patients began experiencing symptoms of illness in mid-December 2019. Clinical isolates were found to contain a novel coronavirus with similarity to bat coronaviruses. As of 28 January 2020, there are in excess of 4,500 laboratory-confirmed cases, with > 100 known deaths. As with the SARS-CoV, infections in children appear to be rare. Travel-relat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
164
0
8

Year Published

2020
2020
2022
2022

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 189 publications
(172 citation statements)
references
References 61 publications
0
164
0
8
Order By: Relevance
“…Most reviews on COVID-19 gave a brief summary of the clinical features [48][49][50][51] and the characteristics of SARS-CoV-2 [52][53][54], as well as recommendations on how to prevent and control [55][56][57][58][59][60] this novel pneumonia. A systematic review [17] explored the possibility of using lopinavir/ritonavir (LPV/r) to treat COVID-19, with the results supporting the use of LPV/r as a part of an experimental regimen for COVID-19 pneumonia treatment.…”
Section: Topicsmentioning
confidence: 99%
“…Most reviews on COVID-19 gave a brief summary of the clinical features [48][49][50][51] and the characteristics of SARS-CoV-2 [52][53][54], as well as recommendations on how to prevent and control [55][56][57][58][59][60] this novel pneumonia. A systematic review [17] explored the possibility of using lopinavir/ritonavir (LPV/r) to treat COVID-19, with the results supporting the use of LPV/r as a part of an experimental regimen for COVID-19 pneumonia treatment.…”
Section: Topicsmentioning
confidence: 99%
“…all the above facts create the need to reconsider the possibility that dogs are intermediate hosts contributing to the extremely high covid-19 transmission in north italy. Possible actions to this direction could include the biased testing of dogs living in houses with positive cases opposed to home quarantine, and non-experimental studies for the investigation of such transmission, using appropriate methodologies such as in silico docking to evaluate the binding of covid-19 with dogs ace2 (16) and sequence-based computational estimations of hosts susceptibility (17).…”
Section: The Question Of Whether Dogs Are Possible Intermediate Hostsmentioning
confidence: 99%
“…However, a number of patients only presented initially with gastrointestinal symptoms. Evidence has shown that human-to-human transmission of SARS-CoV-2 had occurred by close contacts or through virus-laden aerosols [7,8] . The incubation period ranged from 3 days to 14 days [9,10] .…”
Section: Introductionmentioning
confidence: 99%